Podcasts about Efficacy

In this special episode of Skin Anarchy, Dr. Ekta Yadav sits down with supermodel, actress, podcaster, and YSE Beauty founder Molly Sims for an intimate conversation on how beauty evolves, how confidence is built, and how skincare becomes smarter with age. Known for her iconic presence and unfiltered approach on Lipstick on the Rim, Molly opens up about the real experiences that shaped her philosophy — from hormonal acne and melasma to rediscovering balance after years of harsh actives.Molly reflects on her earliest beauty memories, watching her mother turn daily routines into rituals that embodied strength and joy. That foundation, combined with her global modeling career, became its own education: effortless French skincare, British edge, Italian sensuality, and a universal truth — consistency beats extremes.Her journey to creating YSE Beauty began after her skin hit what she calls a “benefit plateau,” when aggressive ingredients stopped delivering results. She shares how shifting toward cushion actives, barrier support, and clinical but sensorial formulations transformed her skin and inspired a brand built on wisdom, simplicity, and results that feel good.For Molly, beauty isn't about correction or perfection — it's about alignment. It's the confidence that comes from choosing what serves you, whether that's a glow-inducing exfoliating pad, a subtle procedure, or simply giving your skin room to breathe.Listen to the full episode to hear Molly Sims discuss aging with intention, building YSE Beauty from the ground up, and why true luxury isn't the price tag — it's how you feel in your own skin.SHOP YSE Beauty and learn more on their social media!CHAPTERS:(0:03) - Introduction & Guest Welcome(1:07) - Early Beauty Memories & “It Girl” Origins(2:44) - Influences From Travel, Fashion & Global Beauty Culture(4:53) - Shifting Aesthetic Trends: From Harsh Treatments to Maintenance(6:59) - Social Media, Filler Culture & Confidence(9:46) - Personal Journeys With Procedures, Aging & Empowerment(12:11) - Why Wise Beauty Was Created(17:05) - Actives, Cushioning Ingredients & the Skin Plateau(21:52) - Luxury vs. Efficacy, Accessibility & Building a Smarter Beauty BrandPlease fill out this survey to give us feedback on the show!Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

In episode 550 of 'Coffee with Butterscotch,' the brothers take a hard look at online ads and why they rarely deliver the wishlist conversions indie devs hope for. They break down misleading metrics, misclicks, and the high cost of chasing visibility through paid channels. The conversation also gets into conventions and showcases, exploring why in-person events are great for networking and playtesting but often fall short as direct sales drivers. It's a grounded look at where marketing effort actually pays off and where it evaporates into thin air.Support How Many Dudes!Official Website: https://www.bscotch.net/games/how-many-dudesTrailer Teaser: https://www.youtube.com/watch?v=IgQM1SceEpISteam Wishlist: https://store.steampowered.com/app/3934270/How_Many_Dudes00:00 Cold Open00:12 Introduction and Welcome02:48 The Role of YouTube Shorts in Game Promotion05:32 Understanding Steam's Algorithm and Wishlist Dynamics08:44 Challenges of Scaling Marketing Efforts11:27 Exploring YouTube Ads and Their Effectiveness14:31 Evaluating the Impact of Advertising on Game Visibility19:54 Navigating Google Ads for Game Promotion22:51 Analyzing Click-Through Rates and Conversions26:07 The Efficacy of YouTube Ads29:45 The Illusion of Effective Advertising34:47 The Uncertainty of Marketing Outcomes41:47 Evaluating Events and Conventions43:09 Digital Events and Showcases45:39 The Challenge of Exclusivity in Marketing49:09 Understanding Randomness in Game Promotion51:45 The Cost-Effectiveness of Marketing Approaches55:02 Balancing Development and Marketing EffortsTo stay up to date with all of our buttery goodness subscribe to the podcast on Apple podcasts (apple.co/1LxNEnk) or wherever you get your audio goodness. If you want to get more involved in the Butterscotch community, hop into our DISCORD server at discord.gg/bscotch and say hello! Submit questions at https://www.bscotch.net/podcast, disclose all of your secrets to podcast@bscotch.net, and send letters, gifts, and tasty treats to https://bit.ly/bscotchmailbox. Finally, if you'd like to support the show and buy some coffee FOR Butterscotch, head over to https://moneygrab.bscotch.net. ★ Support this podcast ★

SummaryIn this conversation, Kimberly interviews best selling author Rachelle Robinette and they discuss the transformative power of herbalism, exploring various herbs for sleep, emotional balance, and hormonal health. They emphasize the importance of food as medicine, the nuances of herb-drug interactions, and the significance of cycling herbs. Rachelle shares personal stories and insights on how herbalism can be integrated into modern life, highlighting the role of bitters in digestion and the holistic approach to health.Sponsors: LMNTOFFER: Right now, for my listeners LMNT is offering a free sample pack with any LMNT drink mix purchase at DrinkLMNT.com/FEELGOOD. That's 8 single serving packets FREE with any LMNT any LMNT drink mix purchase. This deal is only available through my link so. Also try the new LMNT Sparkling — a bold, 16-ounce can of sparkling electrolyte water.USE LINK: DrinkLMNT.com/FEELGOODGLOWING GREENS POWDER OFFER: Go to mysolluna.com and use the CODE: PODFAM15 for 15% off your entire order. USE LINK: mysolluna.com CODE: PODFAM15 for 15% off your entire order. Rachelle Robinette Resources: Website: rachellerobinett.comBook: Naturally, The Herbalist's Guide to Health and TransformationSocial: @rachellerobinettChapters00:00 Introduction to Herbalism02:43 Food as Medicine05:58 Holistic Approach to Health09:01 Efficacy of Herbal Remedies12:03 Cycling and Dependency on Herbs16:15 Exploring Safe Sleep Herbs19:07 Herbs and Autoimmune Conditions22:13 Addressing Brain Fog with Herbalism25:14 The Power of Herbal Combinations28:06 Daily Herbal Practices and Personal Preferences31:11 Heart-Opening Herbs and Emotional Healing34:14 Grounding Herbs for Modern Life37:15 Herbs for Fertility and Hormonal Balance40:18 Bitters and Digestive Health43:08 The Role of the Liver in Hormonal Balance46:09 The Importance of Enjoyable HerbalismSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Major health organizations, including the CDC and ACOG, recommend universal Hepatitis C Virus (HCV) screening for all pregnant women during each pregnancy and at time of delivery. Ideally, pregnant women should be screened for hepatitis C virus infection at the first prenatal visit of each pregnancy. If the antibody screen result is positive, hepatitis C virus RNA polymerase chain reaction testing is done to confirm the diagnosis. The risk of perinatal transmission of HCV is up to 9%, with at least one-third of transmissions occurring antenatally. While antiviral therapy is recommended for Hepatitis B in pregnancy with a viral load greater than 200,000 international units/mL to decrease the risk of vertical transmission, the same is not the case for Hep C. According to the ACOG CPG #6 from September 2023, there are no standard treatment protocols for Hep C in pregnancy but a new publication from the PINK journal (7 Dec 2025) is calling for a change. That new publication is, “Hepatitis C Treatment During Pregnancy: Time for a Practice Change”. Listen in for details. 1. ACOG CPG #6; Sept 20262. Bhattacharya D, Aronsohn A, Price J, Lo Re V. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2023;:ciad319. doi:10.1093/cid/ciad319.3. Chappell CA, Kiser JJ, Brooks KM, et al. Sofosbuvir/¬Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2025;80(4):744-751. doi:10.1093/cid/ciae595.4. Reau N, Munoz SJ, Schiano T. Liver Disease During Pregnancy. The American Journal of Gastroenterology. 2022;117(10S):44-52. doi:10.14309/ajg.0000000000001960.5. Dutra, Karley et al. Hepatitis C Treatment During Pregnancy: Time for a Practice Change. American Journal of Obstetrics & Gynecology MFM, Volume 0, Issue 0, 1018656. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in Pregnancy-Updated Guidelines: Replaces Consult Number 43, November 2017. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Dotters-Katz SK, Kuller JA, Hughes BL. American Journal of Obstetrics and Gynecology. 2021;225(3):B8-B18. doi:10.1016/j.ajog.2021.06.008

In this episode, we review the pharmacology, indications, adverse effects, and unique drug characteristics of 5-HT3 receptor antagonists such as ondansetron (Zofran) and palonosetron (Aloxi). Key Concepts There are four 5-HT3 (serotonin subtype 3) receptor antagonists on the market: ondansetron, granisetron, dolasetron, and palonosetron. These have primarily been studied for acute chemotherapy-induced nausea and vomiting (within 24 hours of chemotherapy administration) and for post-operative nausea and vomiting. When used for chemotherapy-induced nausea/vomiting, 5-HT3 receptor antagonists are given prior to chemotherapy (usually 30-60 minutes before) on day #1. They are not given on subsequent days because they are not as effective for delayed nausea and vomiting. Palonosetron has the longest half-life, longer binding affinity to the 5-HT3 receptor, and trends towards having the best efficacy among the 5-HT3 receptor antagonists. 5-HT3 receptor antagonists are associated with QTc prolongation and may cause headache, dizziness, constipation, or diarrhea. Their association with an increased risk of serotonin syndrome is controversial and not supported from a mechanistic perspective. References Simino GP, Marra LP, Andrade EI, et al. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2016;9(9):1183-1194. doi:10.1080/17512433.2016.1190271 Tricco AC, Soobiah C, Blondal E, et al. Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med. 2015;13:136. Published 2015 Jun 18. doi:10.1186/s12916-015-0371-y Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296 Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024;9(2):102195. doi:10.1016/j.esmoop.2023.102195 Rojas-Fernandez CH. Can 5-HT3 Antagonists Really Contribute to Serotonin Toxicity? A Call for Clarity and Pharmacological Law and Order. Drugs Real World Outcomes. 2014;1(1):3-5. doi:10.1007/s40801-014-0004-3 Li WS, van der Velden JM, Ganesh V, et al. Prophylaxis of radiation-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med. 2017;6(2):104-117. doi:10.21037/apm.2016.12.01

For those asking, here is the overdue podcast release of my debate with Mark Cuban on Covid mandates. We've been aggressively prioritizing promotion of your YouTube channel this past month — something we haven't done before — and we unfortunately got behind on posting on podcast platforms. Moving forward, this will not be an issue. Enjoy the debate if you'd like to listen while driving or doing other activities! SummaryIn this conversation, Mark and I engage in a fiery debate about the COVID-19 pandemic, vaccine mandates, and the implications of free speech in academia. We explore the complexities of public health decisions, the perceived biases in academic discourse, and the evolving understanding of vaccine efficacy and safety. Mark defends the necessity of vaccine mandates for protecting public health, while I raise concerns about the adverse effects and the risk-benefit analysis for young people.—Spotify linkApple link(also available on Overcast and other platforms)—Chapters00:00 Diversity in Hiring: Merit vs. Representation21:11 The Efficacy of Vaccines and Community Health27:10 Vaccine Policies Across Europe33:19 Community Responsibility and Vaccination39:12 Myocarditis Risks and Vaccine Decisions47:06 Accountability for Vaccine Mandates52:40 Understanding Myocarditis Risks: Infection vs. Vaccine58:42 The Role of Comorbidities in COVID Outcomes01:04:01 Analyzing Risk: Vaccination vs. Natural Infection01:09:52 Community Benefit vs. Individual Risk in Vaccination—The Illusion of Consensus is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.illusionconsensus.com/subscribe

Featuring an interview with Dr Priyanka Sharma, including the following topics: Endocrine therapy for hormone receptor-positive, HER2-negative high-risk localized breast cancer (0:00) Johnston SR et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO 2025;Abstract LBA13. Durvalumab in combination with neoadjuvant chemotherapy for localized triple-negative breast cancer (TNBC) (3:25) Loibl S et al. Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC) – Long-term analysis from the GeparNuevo trial. ESMO 2025;Abstract 292MO.  Efficacy and safety findings with TROP2-directed antibody-drug conjugates for metastatic TNBC (5:11) Cortés JC et al. Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i). ESMO 2025;Abstract LBA20.  de Azambuja E et al. Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study. ESMO 2025;Abstract LBA22.  Dent R et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. ESMO 2025;Abstract LBA21.  CME information and select publications

In this episode Ed interviews Dr. Mark Hoddle of University of California Riverside. They discuss some of Mark's worldly adventures while trying to track down biological control agents and his work with the South American palm weevil. Additional Resources Entomology's Indiana Jones Biocontrol lab Center for Invasive Species South American Palm Weevil Time Stamps (01:08:56) Flight Capacity and Energy Dynamics (01:10:23) Analyzing Flight Patterns and Dispersal (01:11:51) Implications of Dispersal Patterns (01:13:55) Urban Environments and Invasive Species (01:15:39) Host Preferences and Economic Impact (01:17:30) Management Strategies for Invasive Weevils (01:19:56) Innovative Control Methods in Agriculture (01:22:01) Economic Considerations in Pest Management (01:24:25) Trapping and Monitoring Techniques (01:27:17) Attract and Kill Strategies (01:30:09) Field Trials and Efficacy of Treatments (01:38:26) Proactive Management of Invasive Pests (01:42:01) Proactive Approaches to Invasive Pests (01:51:44) Biological Control Innovations (01:59:42) Future of Invasive Species Management (02:06:52) Public Awareness and Invasive Species (02:12:22) Closing Thoughts and Resources Zaworski, E. (Host) Hoddle, M. (Interviewee). S4:E42 (Podcast). The Bug Crusade: Adventures of the Indiana Jones of Entomology Part 2. 12/3/2025. In I See Dead Plants. Crop Protection Network.   Transcript

Show Summarywith Lesa Shaw, an experienced Indigenous consultant and community leader with more than 30 years of service across Tribal, federal, state, and municipal sectors. Lesa and I talk about PsychArmor's effort to develop training materials through their effort supporting Native American and Alaska Native Veterans and Service Members. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestLesa Shaw is a tribal leader, public-health consultant, and advocate dedicated to improving health outcomes for Native and Tribal communities, especially Native American veterans. She holds a Master of Public Administration degree from the University of Oklahoma. Over her career, Lesa has held multiple roles across federal, state, tribal, and local government. She has served as a contracting officer and practice manager with the Indian Health Service, worked as a health-policy analyst for tribes, and served as a municipal-level elected official in the city of Shawnee at the request of the central tribes. In tribal service, Lesa has worked to bridge cultural traditions and modern health policy — advocating for culturally respectful care that honors tribal identity and heritage while addressing systemic inequalities in access to care. More recently, she has been part of the advisory committee of PsychArmor 's Native American & Alaska Native Veterans Health & Wellness initiative — helping guide efforts to make veteran care more culturally informed and supportive of Native and Tribal peoples. Lesa remains deeply committed to amplifying the voices of Native veterans and their families, building trust between tribal communities and federal care systems, and laying the groundwork for long-term, culturally grounded health equity.Links Mentioned During the EpisodeBTM214 – Dr. Melita “Chepa” RankBTM 220 – CSM(R) Julia KellyBTM222 – Dean DauphinaisPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course course Understanding the VA for Caregivers. This course helps caregivers navigate and better utilize the services of the VA – the largest integrated healthcare system in the country. The content for this course was developed collaboratively with a working group of various VA Departments. You can find the resource here:  https://learn.psycharmor.org/courses/understanding-the-va-for-caregivers-2 Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

"We bring our patterns with us wherever we go, into every relationship, and we necessarily and inevitably bring them into the therapy relationship or the psychoanalytic relationship, because that's a relationship too. It's not a matter of choice. It simply happens. It happens everywhere. The therapist doesn't do anything to make it happen. This is the human condition. We bring our patterns. The thing that makes psychotherapy, psychotherapy, and not just another relationship, is that we do something different. What we do that's different is, instead of just repeating our same old patterns with a new person, we create the conditions where it becomes possible to notice the patterns, to recognize them, to put words to them, and understand them and discuss them. Out of that experience and that understanding comes the freedom to do things differently, to not have to repeat the same patterns. I always make a point, is that true for everyone? Does everybody need therapy? Well, everybody repeats earlier characteristic patterns. For some people, those patterns allow you to live a satisfying and rewarding life, with pleasure and connection and meaning and intimacy. So if that's the case, you're still repeating early patterns, but that's what it means to be human. However,  some people are living out patterns that cause distress or limitation, that get in the way of living the life they could lead, and that's what we work with in psychotherapy and psychoanalysis." Episode Description: We begin our conversation on the importance of communicating our basic concepts in jargon-free language. Jonathan shares with us the limitations he finds in academic psychology, where analytic ideas are meaningfully misunderstood. We work our way through his paper discussing 'unconscious mental life', the 'mind in conflict', 'disavowal' (instead of 'repression') and 'psychic continuity' (instead of 'psychic determinism') to name but a few of the topics we cover. We recognize the analytic opportunity to discover the ways that we live in the childhood 'then' as opposed to the novel 'now'. Jonathan presents clinical material to demonstrate these concepts, including his own 'disavowal' as he began his analysis. We close with an appreciation of the importance of one's own affective discovery of these otherwise unconscious forces. I also note Jonathan's passion and clarity about our work.   Our Guest: Jonathan Shedler, PhD is an author, consultant, and teacher. His article The Efficacy of Psychodynamic Psychotherapy helped establish psychoanalytic therapy as an evidence-based treatment. He's the author of over 100 scholarly articles, creator of the Shedler-Westen Assessment Procedure (SWAP) for personality diagnosis and case formulation, and co-author of the Psychodynamic Diagnostic Manual. He is Clinical Professor of Psychiatry at UCSF and a Training and Supervising Analyst at the San Francisco Center for Psychoanalysis. Follow Jonathan at: https://jonathanshedler.substack.com/.   Recommended Readings: Schopenhauer's Porcupines by Deborah Luepnitz offers a series of case studies that read like short stories. They will give you a "feel" for what goes on in the clinical consulting room & in the mind of the clinician.   Psychoanalytic Psychotherapy: A Practitioner's Guide by Nancy McWilliams offers a readable introduction to psychodynamic concepts and thinking.    Freud and Man's Soul by Bruno Bettelheim offers real insight into the origins of psychoanalytic theory and how and why it is personally relevant to everyone.    Therapeutic Communication by Paul Wachtel offers answers to the perennial clinician question, "What do I say and how do I say it?"   Long-term Psychodynamic Psychotherapy by Glen Gabbard is the closest thing to a comprehensive course in doing psychodynamic therapy.  Introduction to the Practice of Psychoanalytic Psychotherapy by Alessandra Lema

The Activists and Citizens Forum has described alleged criminal cartel kingpin, Vusimuzi "Cat" Matlala's appearance before Parliament's Ad Hoc Committee, as a waste of time and tax payer money. This comes after Matlala concluded his 2 days of testimony before the committee as members of Parliament investigate allegations of corruption and political interference in the country's justice system. The Forum has also accused Matlala of misdirecting the interaction with Parliamentarians with the aim to protect people who are behind his lavish lifestyle. The committee, has wound up it's work foreo this year but will continue until the 20th of February next year. For a look at what the committee has been able to achieve since it's inception, Jon Gericke spoke to political analyst, Professor Bheki Mngomezulu and Acting Director of the Center for Security, Peace and Conflict Resolution at Nelson Mandela University, Prof Ntsikelelo Breakfast

Today, I am delighted to be joined by a friend and colleague, Mike Mutzel.  Mike has a master's in Clinical Nutrition from the University of Bridgeport. He is a graduate of the IFM, applies functional medicine in clinical practice, and is a consultant lecturer who teaches leading-edge science in a concise format for progressive clinicians to prevent chronic diseases.  In our discussion, Mike and I unpack the benefits of creatine monohydrate, highlighting the importance of ensuring the products we use are free of impurities. We explain how creatine monohydrate gets created, answer many listener questions, and describe current research specific to creatine monohydrate, discussing ways to support bone health, navigate dosing, and how to troubleshoot.  This conversation with Mike Mutzel is truly invaluable, and I look forward to having him back on the podcast to dive a little deeper into the science.  IN THIS EPISODE, YOU WILL LEARN: How creatine supports energy production across muscles, the brain, and other organ systems Why vegetarians and vegans should take creatine What to consider when choosing high-quality creatine supplements Dosing strategies based on diet, exercise, sleep, and individual needs How taking creatine with electrolytes while exercising can improve absorption Benefits of supplementing with amino acids alongside creatine for illness, recovery, or when protein intake is low Adjusting your creatine dosage for sleep, travel, or exercise demands How creatine supports bone and muscle health  The value of creatine for the eyes and ears Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Mike Mutzel On his website YouTube Instagram High Intensity Health Podcast Creatine Research: Creatine in Women's Health: Bridging the Gap From Menstruation Through Pregnancy to Menopause Effects of Creatine and Resistance Training on Bone Health in Postmenopausal Women Creatine Supplementation (3 g/d) and Bone Health in Older Women: A 2-Year, Randomized, Placebo-Controlled Trial Creatine Supplementation in Depression: A Review of Mechanisms, Efficacy, Clinical Outcomes, and Future Directions The Effects of 8-Week Creatine Hydrochloride and Creatine Ethyl Ester Supplementation on Cognition, Clinical Outcomes, and Brain Creatine Levels in Perimenopausal and Menopausal Women (CONCRET-MENOPA): A Randomized Controlled Trial

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Cassie Kline, MD, MAS, about updated efficacy data from the phase 2 FIREFLY-1 study (NCT04775485) of tovorafenib (Ojemda) in patients with relapsed/refractory pediatric low-grade glioma (pLGG) that were presented at the 2025 Society of Neuro-Oncology Annual Meeting. Dr Kline is an attending physician and director of Clinical Research in the Department of Neuro-Oncology at Children's Hospital of Philadelphia in Pennsylvania. In our exclusive interview, Dr Kline discussed longer-term efficacy and safety data from the trial, noting the sustained response rates, continued tumor shrinkage, and rates of patients who remained treatment free after approximately 36 months of follow-up. _____ That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! Thanks again for listening to OncLive On Air. *OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn. This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Please visit answersincme.com/860/99066167-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the efficacy and safety of late-stage biologics in the treatment of CRSwNP. Upon completion of this activity, participants should be better able to: Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.

Please visit answersincme.com/860/99066167-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the efficacy and safety of late-stage biologics in the treatment of CRSwNP. Upon completion of this activity, participants should be better able to: Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.

This week primary care physicians Gary, Henry, Kate and Mark discuss the safety of CBD, a new guideline for managing adults with hypertension, whether COVID-19 vaccines are still effective, and a living guideline from the BMJ to help us choose the best diabetes drugs. Links to stuffEssential Evidence Plus Illinois Academy of Family Physicians meeting Dec 6 in Naperville, IL (Kate, Gary and Mark)   North Dakota Academy of Family Physicians Big Sky Conference Jan 19 in Big Sky, Montana (Gary and Kate) Safety of CBDACC/AHA Hypertension guidelinePREVENT-CVD risk calculatorEfficacy of COVID-19 vaccinesBMJ living guideline for diabetesBMJ MATCH-IT interactive tool for selecting drugs

Dr. Rosensweet graduated from the University of Michigan Medical School in 1968. Since 1971, he has been in private medical practice, with offices in Florida, New Mexico, California, and Colorado. Early in his career, Dr. Rosensweet trained the first nurse practitioners in the United States and was in charge of health promotion for the State of New Mexico.He is a nationally known lecturer and presenter at The American Academy of Anti-Aging Medicine (A4M), The American College for Advancement in Medicine (ACAM), The Age Management Medicine Group (AMMG), and more. In 2019, he was called to Washington to speak in front of The National Academies of Science Engineering and Medicine (NASEM) on “The Safety and Efficacy of Bioidentical Hormones.”Dr. R is the Founder of The Menopause Method and The Institute of BioIdentical Medicine, where he has been training medical professionals to master cBHRT using the most advanced and modern tools. His protocol has been used to treat more than 12,000 women. More about Dr. Rosensweet:* Was recently named one of “The Biggest Names in Anti-Aging Medicine” by The American Academy of Anti-Aging Medicine (A4M)* Author of the books, Menopause and Natural Hormones and Happy Healthy Hormones: How to Thrive in Menopause* Founder of Brite (www.brite.live) and I Wonder, Doctor… (www.iwonderdoctor.com)* Founder and co-chair of the Coalition to Protect Compounded Bioidentical Hormones (cbhrtcoalition.org)*Organizer of a National Summit Committee on the Treatment of Women in Menopause with Bioidentical Hormones* Principal Investigator for a scientific study of female hormones.https://brite.live/       https://iobim.org       https://www.davedrosensweetmd.comhttps://www.facebook.com/share/g/1CEpiqShxB/https://www.instagram.com/menopausedoctor?utm_source=ig_web_button_share_sheet&i“I recommend this product to my clients for hemorrhoids, fissures, itching, irritation, dryness and for any kind of butt drama. I like it because it's all-natural, soothing, effective, multi-purpose and female founded. It's made with healing ingredients such as arnica, vitamin e oil, organic aloe and the branding speaks for itself.” Use code VAGINACOACH to save 20% at www.anythingbrands.comThank you so much for listening! I use fitness and movement to help women prevent and overcome pelvic floor challenges like incontinence and organ prolapse. There is help for women in all life stages! Every Woman Needs A Vagina Coach! Please make sure to LEAVE A REVIEW and SUBSCRIBE to the show for the best fitness and wellness advice south of your belly button. *******************I recommend checking out my comprehensive pelvic health education and fitness programs on my Buff Muff AppYou can also join my next 28 Day Buff Muff Challenge https://www.vaginacoach.com/buffmuffIf you are feeling social you can connect with me… On Facebook https://www.facebook.com/VagCoachOn Instagram https://www.instagram.com/vaginacoach/On Twitter https://twitter.com/VaginaCoachOn The Web www.vaginacoach.comGet your Feel Amazing Vaginal Moisturizer Here

Lachen ist ansteckend – und manchmal die beste Medizin. Beim Lachyoga darf gelacht werden, ohne dass es dafür einen Witz braucht. Es geht nicht um Humor, sondern um das bewusste Erzeugen von Freude durch Bewegung, Atmung und Begegnung.**********An dieser Stelle findet ihr die Übung:00:25:10 - Geleitete Meditation, um das eigenen Lächeln zu kultivieren.**********Quellen aus der Folge:Porras-Jimenez, Y. M., Pancorbo-Hidalgo, P. L., López-Medina, I. M., & Álvarez-Nieto, C. (2025). The role of laughter therapy in adults: Life satisfaction and anxiety control. A systematic review with meta-analysis. Journal of Happiness Studies, 26(6), 1-37. Stiwi, K., & Rosendahl, J. (2022). Efficacy of laughter-inducing interventions in patients with somatic or mental health problems: A systematic review and meta-analysis of randomized-controlled trials. Complementary therapies in clinical practice, 47, 101552. **********Mehr zum Thema bei Deutschlandfunk Nova:Lachflashs: Wir können sie nicht verhindernLachtelefon: Mit fremden Menschen am Telefon albern seinBiologe Tim Hüttner: "Delfine lachen nicht"**********Den Artikel zum Stück findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .**********Ihr habt Anregungen, Ideen, Themenwünsche? Dann schreibt uns gern unter achtsam@deutschlandfunknova.de

Delanie Fischer chats with Jack R. Bialik, technologist and author of Lost in Time: Our Forgotten and Vanishing Knowledge, to explore the mind-bending question: If only a fraction of history is recorded, what has been lost that we're rediscovering—and what has been lost forever? From ancient medical breakthroughs to engineering feats that outperform our modern technology, this episode dives into the forgotten brilliance of past civilizations, the cycles of destruction, and what these revelations mean for us as a society and personally. Episode Highlights:  The Process and Efficacy of Cranial and Cataract Surgery as Early as 800 BC 2010 BC Swords That Are Still Sharp (Plus a New, Old Discovery) An Ancient Battery, Roman Vending Machine, and Superior Concrete Disposal and Sanitation Solutions That Rival and Surpass Modern Systems How Do We Know If We're Interpreting Artifacts Correctly? The Secrets of the Pyramids: Calculations and Construction Theories The Cycle of Destruction and What Could Wipe Out Modern Knowledge What Knowledge of Ours Might Survive a Civilizational Collapse? Wise Practices to Reclaim for Sustainable Living and Preservation What's Stood the Test of Time: Materials, Tools, and Concepts That Endure ⁠CozyEarth.com ⁠- Right now, you can stack my code HELPLESS on top of their sitewide sale - giving you up to 40% off in savings. ____ A quick 5-star rating means so much! ⁠https://podcasts.apple.com/us/podcast/self-helpless/id1251196416⁠ Free goodies like The Quote Buffet + The Watch & Read List: ⁠https://www.selfhelplesspodcast.com/⁠ Ad-free episodes on ⁠Patreon: https://www.patreon.com/selfhelpless⁠ Your Host, Delanie Fischer:⁠ https://www.delaniefischer.com⁠ ____ Related Episodes: 20 Documentaries To Watch This Year: https://www.delaniefischer.com/selfhelplesspodcast/episode/2542cab6/self-helpless-snack-whats-your-favorite-documentary-20-documentaries-to-watch-this-year AI, Robotics, and The Future of Work and Life with Dr. Catie Cuan: https://www.delaniefischer.com/selfhelplesspodcast/episode/2458ba1f/ai-robotics-and-the-future-of-work-and-life-with-dr-catie-cuan The Future of Mental Health and Medicine: Psychedelic Therapy, Technology, and Ancient Healing with Dr. Dave Rabin: https://www.delaniefischer.com/selfhelplesspodcast/episode/f08920eb/the-future-of-mental-health-and-medicine-psychedelic-therapy-technology-and-ancient-healing-with-dr-dave-rabin Learn more about your ad choices. Visit megaphone.fm/adchoices

Show SummaryOn today's episode, we're featuring a conversation with Bob Delaney, a mental health advocate who has also had a full life: a college basketball player, a new jersey state trooper who went undercover in some of the biggest Mob families in new jersey, and his role as a high-profile NBA referee. Bob's insights have been sought after by senior military leadership to speak to troops about mental health and posttraumatic stress. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestBob Delaney is an NBA Cares Ambassador and the Southeastern Conference (SEC) Special Advisor for Officiating Development. He served as the NBA's Vice President of Referee Operations and Director of Officials, after 25 seasons as an NBA referee. Prior to his career in professional basketball, Delaney was a highly decorated New Jersey State Trooper who went undercover to infiltrate the mafia; causing his post-traumatic stress journey. Delaney's firsthand experiences coupled with a passion to better understand mental health make him an expert on the subject. His efforts to educate and bring attention to the topic of post-traumatic stress have entailed visits to military troops around the world, including multiple trips to Afghanistan and Iraq. Described by retired General Robert Brown, U.S. Army Four Star Commander of the Pacific, as the "person who related to soldiers better than any visitor I have seen in my 36 years in the military," Delaney authored a book on the topic, Surviving the Shadows: A Journey of Hope into Post Traumatic Stress. He is also the author of Covert: My Life Infiltrating the Mob. His most recent book - Heroes are Human...Lessons in Resilience, Courage and Wisdom from the COVID Frontlines shares the emotional toll on our healthcare community as they fought an invisible enemy. He has been the subject of numerous media articles and shows including Dr. Sanjay Gupta CNN. Delaney is with the University South Florida Corporate Training and Professional Education Office as Lead Instructor for Trauma Awareness, Resilience, Selfcare programs.Links Mentioned During the EpisodeBob Delaney's Web sitePsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course course Understanding the VA for Caregivers. This course helps caregivers navigate and better utilize the services of the VA – the largest integrated healthcare system in the country. The content for this course was developed collaboratively with a working group of various VA Departments. You can find the resource here:  https://learn.psycharmor.org/courses/understanding-the-va-for-caregivers-2 Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

In this bonus episode of The Alan Sanders Show, we dive into the shocking announcement of Marjorie Taylor Greene resigning from Congress, Justice Samuel Alito's emergency stay blocking a Texas redistricting order and bombshell new data showing flu vaccines with negative efficacy. Then we switch gears for Thanksgiving food talk with guest Valerie Holt. Alan then alludes to the true story of William Bradford and the Pilgrims' first Thanksgiving that you won't hear in school. Then we close with the Vulcan Mind-meld segment with guest BK from BK on the Air. Please take a moment to rate and review the show and then share the episode on social media. You can find me on Facebook, X, Instagram, GETTR,  TRUTH Social and YouTube by searching for The Alan Sanders Show. And, consider becoming a sponsor of the show by visiting my Patreon page!

Fear of virologic failure is a major barrier to ensuring that people living with virally suppressed HIV are receiving the most optimal antiretroviral therapy (ART) regimen for them. Stream this Medical Minute to learn more about key guideline recommendations regarding ART switch and reassuring clinical data regarding efficacy, tolerability, and quality of life associated with switching a suppressive ART regimen. Topics covered include:Efficacy of switching to 2-drug oral ART: real-world evidenceReal-world analyses of virologic failure with switch to long-acting cabotegravir plus rilpivirinePatient selection to reduce risk of virologic failure with switch Regimen-specific switch considerationsPresenters:Dima Dandachi, MD, MPH, FIDSA, FACPAssociate Professor of MedicineDivision of Infectious DiseasesUniversity of MissouriMedical DirectorHIV Treatment and Prevention Program, MUHCMedical DirectorBoone County Public Health and Human ServicesColumbia, MissouriChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationQueen Mary University of LondonFaculty of Medicine and DentistryHonorary Consultant PhysicianBarts Health NHS TrustLondon, United KingdomLink to full program and accompanying slides:https://bit.ly/3KPN0xbGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Tsen Vei Lim speaks to Dr Joshua Garfield, a research fellow at Monash University and Turning Point, Australia. The interview covers Joshua's research article on the efficacy of a personalised alcohol ‘approach bias modification' smartphone app in people accessing outpatient treatment for alcohol use disorders.What is ‘approach bias modification' [01:51]The smartphone app and how it works [04:30]The recruitment process of the randomised controlled trial [07:20]The key findings of the study [09:20]How did the participants of the study feel about using the app? [10:37]The implications of the study for practice [12:33]The next steps for this app and using the app in different populations [13:54]About Tsen Vei Lim: Tsen Vei is an academic fellow supported by the Society for the Study of Addiction, currently based at the Department of Psychiatry at the University of Cambridge. His research integrates computational modelling, experimental psychology, and neuroimaging to understand the neuropsychological basis of addictive behaviours. He holds a PhD in Psychiatry from the University of Cambridge (UK) and a BSc in Psychology from the University of Bath (UK).About Joshua Garfield: Joshua completed a Bachelor of Science with Honours in Psychology at the University of Tasmania in 2002, and then a PhD in Behavioural Neuroscience at the University of New South Wales in 2008, where he studied animal learning theory. Following a brief post-PhD role in depression research, he moved to Melbourne to work for Monash University at Turning Point, an addiction treatment, research, and workforce training institute. Since 2015, he has managed Turning Point's cognitive bias modification research program, led by Professor Victoria Manning.Original article: Efficacy of a personalised alcohol approach bias modification smartphone app in people accessing outpatient alcohol use disorder treatment: A randomised controlled trial https://doi.org/10.1111/add.70184The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

In this episode of The Smart Human Podcast, host Aly welcomes Dr. Robin Mesnage, a toxicologist and research fellow at King's College London, to discuss the toxicology and pharmacology of glyphosate, commonly known as Roundup. The conversation delves into the effects of glyphosate on the microbiome and cellular health, vulnerable periods of exposure, and ways to reduce exposure. Dr. Mesnage also shares insights from a significant 2025 rat study highlighting the carcinogenicity of glyphosate. The discussion extends to the broader implications of pesticide use on human health, food safety, and agricultural practices. Practical tips for reducing exposure to glyphosate and other chemicals at home are also provided. 00:00 Introduction to the Smart Human Podcast 00:50 Meet Dr. Robin Mesnage: Toxicologist and Research Fellow 01:31 Groundbreaking Glyphosate Study 02:27 Study Design and Findings 03:36 Implications of Glyphosate on Human Health 10:20 Glyphosate in Agriculture and Its Widespread Use 17:04 Glyphosate's Impact on the Gut Microbiome 20:58 Daily Exposure to Glyphosate 24:06 Protecting Vulnerable Populations 26:21 Environmental and Airborne Exposure 29:33 The Glyphosate Controversy: Legal Battles and Health Concerns 32:34 The Impact of Glyphosate on Agriculture and Sustainability 36:24 Organic Farming and Certification Standards 39:14 Practical Tips to Reduce Glyphosate Exposure 51:59 The Importance of Healthy Lifestyle and Vulnerable Populations 53:54 Conclusion and Final Thoughts

Featuring an interview with Dr Erika Hamilton, including the following topics: General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00) Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11) Mechanisms of resistance to endocrine therapy (10:08) Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26) Other applications for PROTACs (24:24) Emerging data from the Phase III evERA trial (27:38) Perspectives on clinical investigator and general medical oncologist practice pattern survey results (30:51) CME information and select publications

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients'.

European Study of Prostate Cancer Screening — 23-Year Follow-upAssociation Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressure–Lowering TherapyFurther Reading* Effects of intensive blood-pressure control in type 2 diabetes mellitus* A Randomized Trial of Intensive versus Standard Blood-Pressure ControlSensible Medicine is 100% reader-supported. If you appreciate our work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

Doctors Lisa and Sara talk to Consultant Nephrologist Dr Darren Green about patients with Type 2 Diabetes who also have Chronic Kidney Disease and Heart Failure.  We go through a hypothetical case to illustrate some of the finer points of management that can commonly get missed or might not be appreciated. A really detailed talk full of useful practice enhancing tips for this complex group of patients.  Disclaimer: This episode was supported by Greater Manchester NHS who received support from Boehringer.  You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: Dr Kevin Fernando counselling diabetic patients starting an SGLT2 Inhibitors like Dapagliflozin or Empagliflozin: https://www.youtube.com/watch?v=pc99SdtlsyU Diabetes UK counselling sheets on SGLT2 inhibitors: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/sglt2-inhibitors Kidney Care UK Patient Booklets: https://kidneycareuk.org/get-support/free-resources/patient-information-booklets/ Pumping Marvellous Heart Failure Charity with patient resources: https://pumpingmarvellous.org/ International Society for Nephrology Toolkit for Initiating or Changing RAASi - Renin Angiotensin Aldosterone System Inhibitors (like ACEis such as Lisinopril or Ramipril, or ARBs like Candesartan on Losartan): https://www.theisn.org/initiatives/toolkits/raasi-toolkit/ Royal College of General Practitioners Acute Renal Failure Toolkit: https://elearning.rcgp.org.uk/course/info.php?id=899 CONFIDENCE trial: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2410659 ATLAS trial: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: https://pubmed.ncbi.nlm.nih.gov/11071803/ Metformin lactic acidosis Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review: https://jamanetwork.com/journals/jama/article-abstract/2084896 UK AKI Summit report UKKA AKI Summit Report + Recommendations: https://share.google/7uw1GPQ5sV2riJtiV RCGP AKI follow up  post discharge recommendations: https://bjgpopen.org/content/early/2020/06/15/bjgpopen20X101054/tab-figures-data?versioned=true ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

Dr. Aaron Zelikovich discusses a recent article on nipocalimab and its role in treating generalized myasthenia gravis.  Show citations:  Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116. doi:10.1016/S1474-4422(24)00498-8

Show SummaryNatalie Elliott Handy, a caregiver for her husband and mother and co-host of the Confessions of a Reluctant Caregiver Podcast. During our conversation, we share the commitment that she and her sister have to highlighting and supporting military connected caregivers. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestNatalie is someone who genuinely loves people. She has a natural passion for meeting new faces, staying closely connected with family, friends, and colleagues, and, most of all, helping others. Anyone who knows her will readily say, “Natalie doesn't know a stranger.” It's simply who she has always been.Raised in her family's hardware store, Natalie learned early how to engage customers — and how to count change — by talking to everyone who walked through the door. At church, she was the first to volunteer to sing, recite Bible verses in “big church,” and attend every youth activity, especially lock-ins. In school, her teachers often placed her in the front row to help minimize “distractions,” because she was, without a doubt, a social butterfly.Those gifts — her ability to connect, her quick wit, and her desire to support others — naturally led her into leadership roles throughout her career in the mental health field. She married young at 21 and, many years later, again at 39. She often describes her first marriage as a light-hearted “practice run” with someone kind, but not Jason, the partner she shares her life with today.From the outside, Natalie's life looked picture-perfect: a fulfilling job, a loving husband, a close-knit support system, and of course, her beloved dogs. But behind the scenes, she was burning the candle at both ends — working 12-hour days, six days a week, answering every request with, “No problem. Happy to help.”Everything shifted when Jason was diagnosed with cancer in March 2022. In the midst of that crisis, Natalie confronted the truth that she couldn't keep living at that pace. During those darkest moments, she reconnected with her faith and, through that, rediscovered her true self. She learned to acknowledge her imperfections and, more importantly, to love herself fully — flaws and all.Today, Natalie has reordered her life with clear priorities: God, herself, Jason, family and friends, and then work. She says “no” far more often, seeks silver linings in difficult moments, and is grateful for the journey that led her to live God's plan instead of her own. She embraces the mantra of being “perfectly imperfect.”Her mission is simple: to share stories and experiences that inspire, uplift, and — whenever possible — spark a little laughter. She strives to encourage others to be true to themselves while supporting the people they love. And along the way, she fully intends to keep making new friends.Links Mentioned During the EpisodeConfessions of a Reluctant Caregiver Website2024 Heroes Caring for Heroes series2023 Heroes Caring for Heroes seriesPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course course Understanding the VA for Caregivers. This course helps caregivers navigate and better utilize the services of the VA – the largest integrated healthcare system in the country. The content for this course was developed collaboratively with a working group of various VA Departments. You can find the resource here:  https://learn.psycharmor.org/courses/understanding-the-va-for-caregivers-2 Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

Commentary by Dr. Jian'an Wang.

In this episode, Psychedelic Medicine Podcast host, Dr. Lynn Marie Morski, provides the latest updates from the field of psychedelic medicine. Dr. Morski discusses the breakthrough therapy designation which a number of psychedelic compounds have received in the past few years, the most recent of which is BPL-003, a nasal spray formulation of 5-MeO-DMT. One of the exciting aspects of this new compound, Dr. Morski notes, is that it is shorter-acting than most serotonergic psychedelics—a feature which may make treatment with this substance less expensive and more accessible.  Another exciting development is the COMPASS Pathways phase 3 trial of COMP360 psilocybin. Dr. Morski shares that the company believes they are nine to twelve months ahead of schedule, which means that if all goes well, this psilocybin compound could be approved for treatment resistant depression as early as sometime in 2027. She also discusses why the US FDA said they rejected MDMA for PTSD and what this governing body would like to see from subsequent research before reconsidering this decision. In closing, Dr. Morski shares excitement about the development of novel psychoplastogens—the non-hallucinogenic psychedelics—which may help bring many of the same healing benefits to populations currently unable to be served by the existing compounds under investigation.   In this episode, you'll hear: Which psychedelics currently have breakthrough therapy designation and for which indications Details of recent ketamine research for inpatient depression care and why these results are not as negative as they may seem The current horizons of psychedelic research and what indications may soon be explored Sources of hope in the current state of psychedelic research and the legal landscape   Quotes: "[BPL-003] showed rapid and durable antidepressant outcomes after a single dose. … here we have something that is under an hour [of psychedelic experience] for treatment resistant depression." [7:43] "Keeping patients blinded to whether or not they got the placebo or MDMA is a big focus that [the FDA] wanted to emphasize for these future phase 3 trials." [19:07] "I know we had a big setback last year. I think a lot of us thought by this time we'd be a year into MDMA being approved and we're not. However, there are so many things on the horizon that are worth being excited about." [23:48]   Links: Psychedelic Medicine Podcast on Instagram Psychedelic Medicine Podcast on YouTube Jelovac A, McCaffrey C, Terao M, et al. "Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial" JAMA Psychiatry, 2025. Beckley Psytech Limited Phase 2 Trial: BPL-003 Efficacy and Safety in Treatment Resistant Depression COMPASS Pathways Phase 3 Trial: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD Food and Drug Administration (FDA) Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy for Posttraumatic Stress Disorder Psychedelic Alpha Psychedelic Drug Development Bullseye Chart Psychedelic Medicine Association Porangui

Struggle with your head held high!Text me at 972-426-2640 so we can stay connected!Support me on Patreon!Twitter:  @elliottspeaksInstagram: @elliottspeaks Text me at 972-426-2640 so we can stay connected!Support me on Patreon!Twitter: @elliottspeaksInstagram: @elliottspeaks

In episode #203 we dig into various recovery modalities, evaluating their efficacy and actual relevance for improving recovery times. Some of the modalities covered in this episode  are infrared and traditional saunas, cold water immersion, hot baths, “active recovery”, yoga classes, compression therapy, manual therapy, sleep monitoring devices, and supplements. We highlight the importance of understanding which modalities are truly beneficial and which are likely overhyped.Timestamps:00:00 Introduction to Recovery Modalities12:21 The Importance of Sleep and Nutrition15:17 Sauna: Infrared vs Traditional23:21 Cold Water Immersion and Ice Baths30:22 Hot Baths and Steam Showers35:37 Active Recovery and Recovery Runs35:41 Active Recovery: Rethinking Recovery Methods38:10 The Overrated Nature of Active Recovery39:29 The Role of Movement in Recovery40:48 Yoga: A Mixed Bag for Recovery44:50 Compression Therapy: Benefits and Limitations47:32 The Efficacy of Manual Therapy and Massage53:18 Sleep Monitoring Devices: Are They Worth It?01:00:19 Rest and Sedentarism: Finding Balance01:03:03 Supplements: Overrated or Essential? Work 1:1 with Aaron ⬇️https://strakernutritionco.com/nutrition-coaching-apply-now/Done For You Client Check-In System for Coaches ⬇️https://strakernutritionco.com/macronutrient-reporting-check-in-template/Paragon Training Methods Programming ⬇️https://paragontrainingmethods.comFollow Bryan's Evolved Training Systems Programming ⬇️https://evolvedtrainingsystems.comFind Us on Social Media ⬇️IG | @Eat.Train.ProsperIG | @bryanboorsteinIG | @aaron_strakerYT | EAT TRAIN PROSPER PODCAST

Show SummaryOn today's episode, we're featuring a conversation with Navy Veteran David Boone, a retired Rear Admiral and President and CEO of the San Diego Military Advisory Council or SDMAC. SDMAC is a nonprofit that advocates on behalf of the service members, veterans, and their families in the greater San Diego region. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestSan Diego Military Advisory Council (SDMAC) President and CEO David Boone is the CEO of SDMAC (sdmac.org) which is a nonprofit that advocates, informs and connects the San Diego military with the community, industry and civic leaders. Previously, he provided consulting services for a wide portfolio of clients in the engineering and construction industry. He was the Executive Vice President and Chief Growth Officer for Michael Baker International responsible for both public and private sector development in the consultant and engineering industry from highway and bridges to water, construction services and planning. Prior to that, he was President of CB&I Federal Services and its successor organization, APTIM Government Services. He joined the CB&I team in December 2013 following a 30 year career in the Navy. He began in Strategic Development, and Business Development then promoted to Chief Operating Officer and then President in the Federal sector of Engineering and Construction, Environmental Services, Energy and Base Operating Services.Mr. Boone retired from the US Navy in 2013 as a Navy Civil Engineer Corps Rear Admiral. His last active duty assignment was the Director of Shore Readiness where he was responsible for overseeing facilities and energy funding and policy for 70 bases worldwide – a $9 billion annual budget. His tours as Commanding Officer included Underwater Construction TEAM ONE (Seabees), NAVFAC MARIANAS (Guam), and NAVFAC Mid-Atlantic.Raised in Yokohama, Japan, high school in Oregon, Mr. Boone first attended the University of Oregon and the Oregon Institute of Marine Biology. He then transferred and graduated from Cal Poly SLO in Civil Engineering with Masters degrees in Coastal Engineering and Construction Management from the University of California, Berkeley. He is a registered professional engineer (Virginia and Florida). He was a Navy contracting officer, a Navy Diver, and maintains a TOP SECRET security classification. He received numerous personal Navy awards, including the Nippon Zenkokai Award from the Office of the Prime Minister of Japan. He is currently a member of the Industry Leaders Council with ASCE Industry Leaders Council | ASCE.Links Mentioned During the EpisodeSan Diego Military Advisory CouncilSan Diego Emergency Action GroupPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course Seeking Support. Transitioning from military service can evoke strong emotions. PsychArmor Institute's “Seeking Support” offers service members the tools and resources needed to seek support during and after military transition and into civilian life.   You can find a link to the resource our show notes https://learn.psycharmor.org/courses/Seeking-Support   You can find the resource here:  https://psycharmor.org/podcast/chris-jachemic Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

Overview: In this episode, Dr Joel Gallant gives a history of antiretroviral therapy and HIV drug resistance, drawing on his personal and professional experience beginning in the early 1980s. The views expressed are those of the panelist and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2023 and the content reflects the information available at that time. Guest: Joel Gallant, MD, MPH    For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus    References AIDSVu.org. New HIV diagnoses. 2023. Available from: https://aidsvu.org/local-data/united-states/south/ (Accessed May 19, 2025) AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Alonso A, de Irala J. Strategies in HIV prevention: the A-B-C approach. Lancet 2004;364:1033. Available from: https://doi.org/10.1016/s0140-6736(04)17050-5 Bacheler L, Jeffrey S, Hanna G et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999–5008. Available from: https://doi.org/10.1128/jvi.75.11.4999-5008.2001 Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–71. Available from: https://doi.org/10.1126/science.6189183 Bayer R, Edington C. HIV testing, human rights, and global AIDS policy: exceptionalism and its discontents. J Health Polit Policy Law 2009;34:301–23. Available from: https://doi.org/10.1215/03616878-2009-002 Centers for Disease Control and Prevention. Pneumocystis pneumonia – Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm Centers for Disease Control and Prevention. Preventing HIV. 2024. Available from: https://www.cdc.gov/hiv/prevention/index.html (Accessed May 22, 2025) Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. Available from: https://doi.org/10.1056/NEJMoa1105243 Cuevas JM, Geller R, Garijo R et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015;13:e1002251. Available from: https://doi.org/10.1371/journal.pbio.1002251 Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy (Accessed May 19, 2025) Dragovic G. Acute pancreatitis in HIV/AIDS patients: an issue of concern. Asian Pac J Trop Biomed 2013;3:422–425. Available from: https://doi.org/10.1016%2FS2221-1691(13)60091-X Eron JJ, Benoit SL, Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662–9. Available from: https://doi.org/10.1056/nejm199512213332502 Gandhi RT, Tashima KT, Smeaton LM et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS clinical trials group A5241 (OPTIONS). J Infect Dis 2020;221:1407–15. Available from: https://doi.org/10.1093/infdis/jiz281 Getting to Zero San Francisco. HIV epidemiology annual report 2017. 2022. Available from: https://gettingtozerosf.org/getting-to-zero-resources/hiv-report-2017/ (Accessed May 22, 2025) Global Fund. About the Global Fund. 2024. Available from: https://www.theglobalfund.org/en/about-the-global-fund/ (Accessed May 19, 2025) Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429–41. Available from: https://doi.org/10.1056/NEJMoa0803152 Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734–9. Available from: https://doi.org/10.1056/nejm199709113371102 Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11–8. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b47 HIV Prevention Trials Network. HPTN 052. 2023. Available from: https://www.hptn.org/research/studies/hptn052 (Accessed May 19, 2025) HIV.gov. HIV and AIDS timeline. 2024. Available from: https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline/ (Accessed May 19, 2025) HIVinfo.NIH.gov. FDA approval of HIV medicines. 2024. Available from: https://hivinfo.nih.gov/understanding-hiv/infographics/fda-approval-hiv-medicines (Accessed May 19, 2025) i-base. Cross-resistance by drug class. 2025. Available from: https://i-base.info/guides/changing/cross-resistance (Accessed May 19, 2025) Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 2014;6:4095–139. Available from: https://doi.org/10.3390/v6104095 Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175–85. Available from: https://doi.org/10.1056/NEJMoa035026 Landovitz RJ, Donnell D, Clement ME et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021;385:595–608. Available from: https://doi.org/10.1056/NEJMoa2101016 Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–4. Available from: https://doi.org/10.1126/science.2467383 Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007;44:179–87. Available from: https://doi.org/10.1097/01.qai.0000247229.68246.c5 Lucas C. The San Francisco model and the nurses of Ward 5B. Lancet HIV 2019;6:E819. Available from: https://doi.org/10.1016/S2352-3018(19)30267-X Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29–38. Available from: https://doi.org/10.1016/s0140-6736(07)61047-2 Marcelin AG. Resistance to nucleoside reverse transcriptase inhibitors. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 1. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2241/ Margolis AM, Heverling H, Pham PA et al. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26–39. Available from: https://doi.org/10.1007/s13181-013-0325-8 Moore RD, Creagh-Kirk T, Keruly J et al. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group. Arch Intern Med 1991;151:981–6. Available from: https://doi.org/10.1001/archinte.1991.00400050123023 National Institute of Allergy and Infectious Diseases. HIV Undetectable = Untransmittable (U = U), or treatment as prevention. 2019. Available from: https://www.niaid.nih.gov/diseases-conditions/treatment-prevention (Accessed May 19, 2025) Nelson MR, Katlama C, Montaner JS et al. The safety of […] for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273–81. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b33 New York State Department of Health. Pre-exposure prophylaxis (PrEP) to prevent HIV infection: question and answers. 2012. Available from: https://www.health.ny.gov/publications/0265/ (Accessed May 22, 2025) Overton ET, Richmond G, Rizzardini G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis 2023;76:1646–54. Available from: https://doi.org/10.1093/cid/ciad020 Pollak EB, Parmar M. Indinavir. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554396/ (Accessed May 19, 2025) Richman DD, Fischl MA, Grieco MH et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192–7. Available from: https://doi.org/10.1056/nejm198707233170402 Schmit JC, Ruiz L, Clotet B et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995–9. Available from: https://doi.org/10.1097/00002030-199610090-00010 Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9:727–8. Available from: https://doi.org/10.1038/nm880 Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339–54. Available from: https://doi.org/10.1056/NEJMoa0708975 TIME. Man of the year. 1996. Available from: https://time.com/vault/issue/1996-12-30/page/1/ (Accessed May 19, 2025) U.S. President's Emergency Plan for AIDS Relief (PEPFAR). About us. 2025. Available from: https://www.state.gov/about-us-pepfar/ (Accessed May 19, 2025)

**In this episode, Dr. Lisa Faast sits down with Craig Presser and Ryan from Skinesa to explore how a dermatologist-developed probiotic is redefining skin health — and helping independent pharmacies grow revenue through innovative wellness solutions. In this conversation: -How Skinesa supports acne, eczema, and rosacea through the gut-skin connection -The science behind dermatology probiotics and what makes Skinesa unique -How pharmacies can easily integrate Skinesa into their supplement lineup -Education strategies to help patients understand gut and skin wellness** **Show Notes:** 1. **Intro** [0:00] 2. **Introduction to Skinesa and Its Unique Probiotic** [0:01] 3. **Clinical Breakdown and Research Background** [2:57] 4. **Challenges and Efficacy in the European Market** [4:45] 5. **Personal Experiences and Clinical Insights** [7:11] 6. **Business Opportunities for Independent Pharmacies** [11:04] 7.**Marketing and Distribution Strategies** [14:24] 8.**Patient Testimonials and Clinical Evidence** [15:21] 9.**Conclusion and Contact Information** [18:50] **Website mentioned in this episode:** Contact Skinesa https://www.skinesa.com/  ----- #### **Becoming a Badass Pharmacy Owner Podcast is a Proud to be Apart of the Pharmacy Podcast Network**

The November 2025 Recall revisits four insightful episodes centered on muscle and neuromuscular diseases. Kicking off the episode is a two-part series on myositis, where Dr. Stacey Clardy speaks with Dr. Andrew Mammen. The episode continues with an interview featuring Dr. Eric Voorn, who discusses the effectiveness of combining personalized, home-based aerobic exercise with coaching to improve physical fitness in individuals with neuromuscular diseases. The episode wraps up with Dr. Elia Sechi discussing the critical role of interpreting lab test results, understanding assay performance, and recognizing the real-world impact of false positives in myasthenia gravis diagnostics.  Podcast links: Updates on All Things Myositis – Part 1  Updates on  All Things Myositis - Part 2 Efficacy of Aerobic Exercise and Coaching on Physical Fitness in Neuromuscular Disease  False Positivity of Acetylcholine Receptor Autoantibodies in Clinical Practice Article links: Efficacy of Combined Aerobic Exercise and Coaching on Physical Fitness in People With Neuromuscular Diseases Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice Show citations:  Oorschot S, Brehm MA, van Groenestijn AC, et al. Efficacy of Combined Aerobic Exercise and Coaching on Physical Fitness in People With Neuromuscular Diseases: A Randomized Clinical Trial. Neurology. 2025;105(1):e213781. doi:10.1212/WNL.0000000000213781 Zara P, Chessa P, Deiana GA, et al. Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice. Neurology. 2025;104(9):e213498. doi:10.1212/WNL.0000000000213498 Disclosures can be found at Neurology.org.   

Send us a textWelcome back Rounds Table Listeners! In this throwback episode (initial release 14 Mar 2024), Dr. Mike Fralick and special guest, Dr. Laiya Carayannopoulos from the Intern at Work Podcast, discuss two papers: one exploring the role of non-invasive ventilation in comatose patients after acute poisoning, and and one on the use of the PEN-FAST Score in the point-of-care risk assessment of penicillin allergy. Two papers, here we go!Effect of Noninvasive Airway Management of Comatose Patients With Acute Poisoning (0:00 – 16:25).Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy (16:26 – 24:17).And for the Good Stuff:Celebrating Research Success! (24:18 – 25:14).Non-inferiority results: everything you need know in 5 minutes! and Is Noninferior Not Inferior? (25:15 – 26:48).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Topics covered:  Are oral GLP-1s as effective as injectables? What's the deal with the new report on protein powders containing lead? Should I worry about not having carbs with my protein after a workout? Are energy drinks really killing my gains in the gym and workouts? Consumer Report on protein powders Podcast with Dyllon Sanford on GLP-1-Part 1.  European Food Safety Authority

Show SummaryOn today's episode, we're featuring a conversation with Army Combat Veteran Jaymes Poling and Modern Warrior LIVE — a powerful blend of personal storytelling and music that explores the emotional weight of war and the journey toward healing.Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestJaymes Poling is a former infantry leader in the 82nd Airborne Division who served three years in Afghanistan. After coming home, he turned to writing to make sense of his experience, which led to the creation of Modern Warrior LIVE — a powerful blend of personal storytelling and music that explores the emotional weight of war and the journey toward healing.He's since become a speaker and mental health advocate, working with veterans, first responders, and trauma survivors across the country. Through hundreds of engagements nationwide, Jaymes brings a raw, honest voice to conversations about leadership, community, and post-traumatic growth. Links Mentioned During the EpisodeModern Warrior Live Web SitePsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course Supporting Someone with Invisible Wounds. Not all wounds can be seen, and invisible wounds are just as serious as visible ones. This course introduces the four main types of invisible wounds - Posttraumatic Stress Disorder, Traumatic Brain Injury, Substance Use Disorder, and Depression.   You can find the resource here:  https://learn.psycharmor.org/courses/supporting-someone-with-invisible-wounds    Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

In episode 65 we discuss varenicline and bupropion for alcohol use disorder.  Söderpalm B, Lidö H, Franck J, Håkansson A, Lindqvist D, Heilig M, Guterstam J, Samuelson M, Askerup B, Wallmark-Nilsson C, de Bejczy A. Efficacy and safety of varenicline and bupropion, in combination and alone, for alcohol use disorder: a randomized, double-blind, placebo-controlled multicentre trial. Lancet Reg Health Eur. 2025 May 13;54:101310.     We also discuss medical marijuana for anxiety in Pennsylvania, and RFK's embrace of psychedelic therapy.  Annals of Internal Medicine: Medical Cannabis Certifications After Pennsylvania Added Anxiety Disorders as a Qualifying Condition  Annals of Internal Medicine: High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes: A Systematic Review  MedPageToday: Will RFK Jr.'s Push for Psychedelic Therapy Help or Hamper the Emerging Field?  ---  This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, visit MI CARES.  CME: https://micaresed.org/courses/podcast-addiction-medicine-journal-club/   ---  Original theme music: composed and performed by Benjamin Kennedy  Audio editing: Michael Bonanno  Executive producer: Dr. Patrick Beeman  A podcast from Ars Longa Media  ---  This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.   ---  The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group.  Email: addictionmedicinejournalclub@gmail.com   Facebook: @AddictionMedJC  Facebook Group: Addiction Medicine Journal Club  Instagram: @AddictionMedJC   Threads: @AddictionMedJC  YouTube: addictionmedicinejournalclub   Twitter/X: @AddictionMedJC    ---  Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities. Learn more about your ad choices. Visit megaphone.fm/adchoices

Here is a real-world clinical case with a tricky differential: Our team recently readmitted a patient 6 days postpartum/post C-section (which was done for ICP and fetal macrosomia at close to 4500 grams, with A2GDM). She had elevated blood pressures, a frontal headache, some midepigastric pain/RUQ discomfort. Pretty clear picture right: sounds like preeclampsia (PreE) with severe features based on BP elevation and symptoms. So, we started her on mag-sulfate per protocol. Well, her transaminases were in the 400-600s, which was significantly higher than they were at delivery. They then peaked the next day at 900! OK, it still meets criteria for PreE with severe features. But could this also be postpartum Acute fatty Liver of Pregnancy (AFLP)? The clinical picture of these 2 conditions may overlap but there are distinct differences here. AFLP is potentially fatal, so we have to get that diagnosis correct. How can we distinguish AFLP from PreE with severe features or HELLP? Listen in for details.1. https://www.preeclampsia.org/the-news/health-information/acute-fatty-liver-of-pregnancy-can-be-confused-with-preeclampsia-and-hellp-syndrome2. Yemde A Jr, Kawathalkar A, Bhalerao A. Acute Fatty Liver of Pregnancy: A Diagnostic Challenge. Cureus. 2023 Mar 26;15(3):e36708. doi: 10.7759/cureus.36708. PMID: 37113350; PMCID: PMC10129069.3. Maalbi O, Elachhab N, Elkabbaj A, Arfaoui M, Hindi S, Lahbabi S, Oudghiri N, Tachinante R. Management of Acute Fatty Liver of Pregnancy: A Retrospective Study of 12 Cases Compared With Data in the Literature. Cureus. 2025 Jun 11;17(6):e85753. doi: 10.7759/cureus.85753. PMID: 40656400; PMCID: PMC12247011.4. Siwatch S, De A, Kaur B, et al. Safety and Efficacy of Plasmapheresis in Treatment of Acute Fatty Liver of Pregnancy-a Systematic Review and Meta-Analysis.Frontiers in Medicine. 2024;11:1433324. doi:10.3389/fmed.2024.1433324.5. Sarkar M, Brady CW, Fleckenstein J, et al.6. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology (Baltimore, Md.). 2021;73(1):318-365. doi:10.1002/hep.31559.STRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG

AI in behavioral health demands a balanced strategy that protects consumers, enables innovation, and expands access at scale.  In this episode, Dr. Zach Boyd, Director of Utah's Office of Artificial Intelligence Policy, shares how his team is creating practical guardrails for responsible AI in healthcare. He traces his path from theoretical math to social science, noting that behavioral health is the front line for AI's impact. Early milestones include broad stakeholder surveys, privacy and advertising protections, detailed guidance for professionals, and a safe harbor to reduce regulatory uncertainty. Dr. Boyd highlights opportunities in clinical automation and consumer tools, while warning about risks like deepfakes and urging leaders to balance safety, efficacy, and access. Tune in and learn how thoughtful policy can accelerate safer, more equitable behavioral health innovation! Resources: Connect with and follow Dr. Zach Boyd on LinkedIn. Learn more about Utah's Office of Artificial Intelligence Policy here. Email Utah's Office of Artificial Intelligence Policy directly here.

A meta-analysis of low-carb diets for diabetes remission found little to no effect at 12 months, clinically important harms to quality of life, and the deal-killer––an increase in LDL cholesterol.